Adaptive Biotechnologies CORP Form 4 insider transactions

Adaptive Biotechnologies Corp's President and COO, Julie Rubinstein, reported multiple sales and exercises of common stock and options under a pre-arranged trading plan.

Adaptive Biotechnologies Director Michelle Renee Griffin sold 15,394 shares of common stock for a weighted-average price of $13.91 per share.

Adaptive Biotechnologies' Chief People Officer, Francis Lo, sold 30,593 shares of common stock under a pre-arranged trading plan.

Adaptive Biotechnologies' Chief Commercial Officer, Susan Bobulsky, sold 41,338 shares of common stock at $13.17 per share to cover tax withholding obligations related to RSU vesting.

Adaptive Biotechnologies' Chief Commercial Officer, Sharon Benzeno, sold 63,103 shares of common stock at $13.17 per share to cover tax withholding obligations related to RSU vesting.

Adaptive Biotechnologies' CFO, Kyle Piskel, sold 18,672 shares of common stock at $13.17 per share to cover tax withholding obligations related to RSU vesting.

Adaptive Biotechnologies' Chief Scientific Officer, Harlan S. Robins, sold 470,266 shares of common stock to cover tax withholding obligations related to RSU and performance share unit vesting.

Adaptive Biotechnologies CEO Chad M. Robins sold 470,167 shares of common stock for $6.19 million to cover tax obligations from RSU and PSU vesting.

Adaptive Biotechnologies Director Peter M. Neupert acquired 15,625 shares of common stock at a $0 price.

Adaptive Biotechnologies Corp. Director Robert Hershberg acquired 15,625 shares of common stock, increasing his beneficial ownership.

Adaptive Biotechnologies' Chief People Officer, Francis Lo, reported the acquisition of 44,063 shares of common stock.

Adaptive Biotechnologies' Chief Commercial Officer, Susan Bobulsky, acquired 121,875 shares of common stock through two transactions.

Adaptive Biotechnologies' Chief Commercial Officer, Sharon Benzeno, acquired 39,063 shares of common stock at a price of $0, increasing her beneficial ownership.

Adaptive Biotechnologies' President and COO, Julie Rubinstein, acquired 81,250 shares of common stock on March 4, 2026.

Adaptive Biotechnologies' Chief Scientific Officer, Harlan S. Robins, increased his direct beneficial ownership of common stock through the vesting of performance share units.

Adaptive Biotechnologies' Chief Financial Officer, Kyle Piskel, acquired 61,875 shares of common stock at a price of $0.

Adaptive Biotechnologies Director Katey Einterz Owen acquired 15,625 shares of common stock on March 4, 2026, increasing her direct beneficial ownership to 88,254 shares.

Adaptive Biotechnologies Director Michelle Renee Griffin acquired 15,625 shares of common stock, increasing her beneficial ownership to 31,019 shares.

Adaptive Biotechnologies CEO and Chairman Chad Robins reported significant acquisitions of company common stock through performance share unit vesting and other grants.

Adaptive Biotechnologies Director Michelle Griffin exercised options and subsequently sold 48,044 shares of common stock under a pre-arranged 10b5-1 trading plan.

Adaptive Biotechnologies' President and COO, Julie Rubinstein, executed pre-planned option exercises and subsequent sales of company stock.

Adaptive Biotechnologies' Chief Scientific Officer, Harlan S. Robins, sold a total of 24,233 shares of common stock in early March 2026 under a pre-arranged trading plan.

Adaptive Biotechnologies CEO Chad M. Robins filed a Form 4 detailing planned future sales of common stock under a Rule 10b5-1 trading plan.

Adaptive Biotechnologies CFO Kyle Piskel exercised stock options and immediately sold an equivalent number of shares under a pre-arranged 10b5-1 trading plan.

Adaptive Biotechnologies' Chief Scientific Officer, Harlan S. Robins, reported the sale of 42,788 shares of common stock through a pre-arranged 10b5-1 trading plan.

Adaptive Biotechnologies CEO and Chairman Chad M. Robins sold 124,998 shares of common stock for a weighted average price of $18.44 per share under a pre-arranged trading plan.

Adaptive Biotechnologies' Chief People Officer, Francis Lo, exercised stock options and sold common stock totaling 79,590 shares on January 12, 2026, under a pre-arranged 10b5-1 trading plan.

Adaptive Biotechnologies CFO Kyle Piskel exercised stock options and subsequently sold 4,290 shares of common stock under a pre-arranged 10b5-1 trading plan.

Adaptive Biotechnologies' Chief Scientific Officer, Harlan S. Robins, sold 10,000 shares of common stock for a weighted average price of $16.44 per share.

Adaptive Biotechnologies' Chief People Officer, Francis Lo, exercised stock options and subsequently sold a portion of the acquired common stock under a pre-arranged 10b5-1 trading plan.